Medical Weight Loss in Australia: Treatments, Safety, Costs and What to Expect

Medical weight loss refers to evidence-based treatment for weight management delivered under the supervision of qualified healthcare professionals.

In Australia, medical weight loss may involve lifestyle support, behavioural strategies, prescription treatment, pathology testing, and ongoing medical care tailored to a patient's individual health needs and goals.

While many people associate medical weight loss with newer prescription medications, modern obesity care is broader than medication alone. Weight management can involve hormonal, metabolic, psychological, behavioural, and lifestyle factors, and treatment often works best when these areas are considered together.

Around two-thirds of Australian adults are now classified as overweight or obese according to the Australian Institute of Health and Welfare, making obesity one of Australia's largest long-term health challenges.

Medical weight loss care can include GPs, telehealth doctors, dietitians, psychologists and other healthcare professionals. If you are considering treatment, a doctor-led weight loss consultation can help assess suitability, risks, costs and next steps.

Medical weight loss is the treatment of overweight and obesity using evidence-based healthcare approaches supervised by qualified clinicians.

Unlike general dieting programs or wellness trends, medical weight loss focuses on understanding the factors that may contribute to weight gain or difficulty losing weight.

Treatment may involve:

• medical assessment
• lifestyle and behavioural strategies
  prescription treatment where appropriate
• pathology testing
• sleep studies
• ongoing monitoring and follow-up care
• referrals to allied health professionals or specialists

Modern medical understanding increasingly recognises obesity as a complex chronic health condition rather than simply a matter of willpower or personal discipline.

 

Medical weight loss treatment may be considered for adults who:

• have struggled to lose weight despite lifestyle changes
• have a BMI in the overweight or obesity range
• have weight-related health conditions
• are seeking medically supervised treatment
• want evidence-based support rather than general dieting advice

Doctors may also consider health factors such as:

• blood sugar concerns
• sleep apnoea
• blood pressure
• cholesterol
• hormonal conditions
• mobility limitations
• mental health
• medications that may affect weight

Suitability for treatment varies between individuals and should always be assessed by a qualified healthcare professional.

Medical weight loss treatment is highly individualised and may involve several different approaches used together.

Lifestyle support remains an important part of weight management, even when prescription treatment is used.

This may include:

• nutrition guidance
• physical activity support
• sleep optimisation
• behavioural strategies
• emotional eating support
• stress management

For many patients, sustainable long-term change often involves more than calorie restriction alone.

Several different categories of prescription treatment may be used in medical weight management, depending on a patient's health profile, treatment goals, and clinical suitability.

One of the major developments in recent years has been the rise of incretin-based therapies, including GLP-1 receptor agonists and dual incretin therapies, which work by influencing appetite regulation, fullness signals, gastric emptying, and metabolic pathways involved in hunger and blood sugar control.

These treatments are commonly administered as weekly or daily injections, although oral formulations are also emerging internationally.

Other prescription weight loss medications may work through different mechanisms, including:

• appetite suppression
• increasing feelings of fullness
• influencing reward or craving pathways in the brain
• reducing absorption of dietary fat
• supporting blood sugar regulation and metabolic health

Depending on the treatment type, medications may be available as:

• injectable treatments
• oral medications
• daily or weekly formulations
• longer-acting therapies

Different medication categories have different levels of evidence, expected weight loss outcomes, side effect profiles, contraindications, and monitoring requirements.

Not all treatments are suitable for every person, and prescription treatment should always involve medical assessment, discussion of risks and benefits, and ongoing follow-up care.

Under Australian regulations, prescription weight loss treatment can only be prescribed where clinically appropriate.

Weight management may sometimes involve identifying health factors that can contribute to weight gain or difficulty losing weight.

Depending on the situation, doctors may recommend:

• blood tests
• diabetes screening
• cholesterol testing
• thyroid assessment
• liver function testing
• sleep studies for sleep apnoea

Addressing medical contributors can sometimes improve long-term treatment outcomes.

In recent years, incretin-based therapies, including GLP-1 receptor agonists and newer dual incretin medications, have significantly changed the landscape of medical weight management.

Clinical trials of these newer treatments have demonstrated substantially greater average weight loss than older medication approaches when combined with ongoing lifestyle support and medical supervision.

In some studies, participants using newer hormonal and appetite-regulating therapies achieved average weight reductions of approximately 10-20% of body weight over time, although individual results can vary considerably.

For context, a person weighing 120 kg who loses 15% of their body weight would lose approximately 18 kg.

Older prescription medication categories may still play a role for some patients depending on their medical history, treatment goals, contraindications, side effect tolerance, and cost considerations.

Outcomes may depend on factors including:

• treatment adherence
• baseline health
• sleep and stress
• side effects
• nutrition and physical activity
• ongoing medical follow-up
• individual biological response

It is important to understand that these treatments are not suitable for everyone and should only be used under appropriate medical supervision.

For many patients, treatment works best when combined with sustainable changes in eating habits, physical activity, sleep, and overall health behaviours.

Several major international studies have demonstrated meaningful improvements in weight and metabolic health using newer incretin-based prescription treatments alongside lifestyle support.

Potential benefits reported in clinical studies have included:

• reduced body weight
• improved blood sugar control
• reduced waist circumference
• improvements in cardiovascular risk factors
• improvements in mobility and sleep-related symptoms in some patients

The SELECT cardiovascular outcomes trial also demonstrated reductions in major cardiovascular events in some patients with obesity and established cardiovascular disease.

Patients interested in the evidence can review the STEP clinical trial program, SURMOUNT clinical trial program, SELECT cardiovascular outcomes trial, and Australian obesity management guidance. Reference links are listed at the end of this article.

Weight regain after stopping treatment is an important and widely discussed topic in medical weight management.

Research suggests that some patients may regain part of the weight lost after discontinuing prescription treatment, particularly after stopping incretin-based therapies such as GLP-1 receptor agonists or dual incretin medications.

This may occur if appetite regulation, eating patterns, physical activity, or lifestyle factors become difficult to maintain over time after treatment cessation.

This does not mean treatment has failed. Obesity is increasingly understood as a chronic health condition, and long-term management may be needed for some people, similar to other chronic medical conditions.

Approaches to long-term management can vary between individuals.

For some patients, doctors may discuss:

• gradually reducing treatment over time
• lower-dose maintenance approaches
• transitioning from injectable to oral therapies in future
• ongoing monitoring and follow-up care
• transitioning focus toward lifestyle and behavioural support
• increasing physical activity as mobility and energy improve
• building sustainable nutrition and sleep habits
• addressing emotional eating or psychological factors contributing to weight gain

For others, longer-term treatment may be considered appropriate depending on medical history, risk factors, treatment response, and individual goals.

This is one reason medical follow-up and health support can remain important even after significant weight loss occurs.

Many experts now view successful long-term treatment not simply as losing weight initially, but as maintaining health improvements sustainably over time.

Like all medical treatments, prescription weight loss treatments can involve risks and side effects.

Potential side effects vary depending on the medication category and the individual patient.

For example, incretin-based therapies such as GLP-1 receptor agonists commonly involve gastrointestinal side effects, particularly when treatment first begins or doses increase.

Depending on the treatment type, possible side effects may include:

• nausea
• vomiting
• constipation
• diarrhoea
• abdominal discomfort
• fatigue
• headaches
• changes in appetite

Different medication categories also have different contraindications, precautions, and monitoring requirements.

Some treatments may not be appropriate for people with certain medical conditions, medication histories, gastrointestinal disorders, or pregnancy considerations.

This is why proper medical assessment and ongoing follow-up care are important parts of safe treatment.

Patients should seek medical advice promptly if concerning symptoms develop during treatment.

Weight management treatment may affect more than body weight alone.

For some patients, treatment may also contribute to improvements in:

• blood sugar management
• sleep apnoea symptoms
• blood pressure
• cholesterol
• mobility and joint pain
• energy levels
• confidence and wellbeing
• cardiovascular risk factors

Even modest weight loss of 5-10% of body weight can sometimes lead to meaningful improvements in metabolic health and obesity-related conditions.

Some incretin-based therapies have also demonstrated cardiovascular and metabolic benefits in selected patient populations within major clinical trials.

The health impact of treatment often depends on individual circumstances and underlying medical conditions.

Medical weight loss treatment is not always managed by doctors alone.

Depending on a patient's needs, allied health professionals and specialists may play an important role in long-term care.

This may include support from:

• dietitians
• psychologists
• exercise physiologists
• endocrinologists
• sleep physicians
• bariatric specialists

For example:

• a dietitian may help patients build sustainable eating patterns
• a psychologist may assist with emotional eating or behavioural challenges
• an exercise physiologist may help design safe physical activity plans
• a sleep physician may investigate sleep apnoea or fatigue contributing to weight gain

For some patients, a multidisciplinary approach may improve long-term treatment outcomes and overall health.

The cost of medical weight loss treatment in Australia can vary significantly depending on:

• consultation fees
• medication category and formulation
• pharmacy pricing
• pathology testing
• follow-up frequency
• whether services operate through subscriptions or pay-as-you-go care

At Doctors for Weight Loss, telehealth consultations are offered on a flexible pay-as-you-go basis.

Current pricing is:

• Initial consultation: $89.99
• Follow-up consultations: $59.99

If prescription treatment is considered clinically appropriate, patients receive an eScript which can be filled at a pharmacy of their choice.

Medication pricing can vary substantially depending on:

• the medication category
• dosage
• pharmacy pricing
• medication availability
• whether compounded or brand products are involved

As a broad guide, newer incretin-based therapies in Australia may cost anywhere from approximately $250-$600+ per month through standard retail pharmacies, depending on the product and dose prescribed. Pharmacy pricing can fluctuate over time and may differ between providers such as Chemist Warehouse and independent pharmacies.

Older prescription medication categories may sometimes cost less, although suitability and effectiveness vary between treatments and individuals.

Some online services bundle consultations, medication supply, coaching, and delivery into ongoing subscription programs, while others separate consultation costs from pharmacy dispensing fees.

Patients should clarify:

• whether medication costs are included
• whether subscriptions are ongoing
• how follow-up appointments are billed
• whether pharmacy choice is restricted
• whether additional investigations may be required

Understanding the total expected cost can help patients make more informed decisions before starting treatment.

Patients in Australia may access medical weight loss treatment through several different pathways.

Some patients choose to discuss weight management with their regular GP, particularly if they already have an established medical relationship and ongoing healthcare needs.

Benefits may include continuity of care and existing knowledge of the patient's medical history.

Telehealth weight loss services allow patients to speak with Australian doctors remotely through secure video or phone consultations.

Potential advantages may include:

• faster appointment access
• convenience from home
• accessibility for regional and rural patients
• flexible follow-up care
• eScripts sent directly to a phone where appropriate

Some telehealth services operate more like traditional GP care, while others may focus more heavily on subscriptions or app-based systems.

Doctors for Weight Loss offers doctor-led telehealth consultations on a flexible pay-as-you-go basis, without lock-in subscriptions or bundled medication delivery requirements.

Some providers offer structured subscription programs that bundle consultations, support tools, coaching, and medication delivery into recurring memberships.

For some patients, these programs may provide convenience, accountability, and ongoing engagement.

Others may prefer greater flexibility, independent pharmacy access, or more traditional doctor-led care models.

Medical weight loss treatment continues to evolve rapidly.

Research is ongoing into newer incretin therapies, combination medications, and oral formulations designed to improve convenience and long-term treatment outcomes.

While injectable GLP-1 receptor agonists and dual incretin therapies currently receive significant public attention, oral medications targeting similar hormonal and appetite pathways are also being studied internationally and may become more widely available in Australia in coming years, subject to regulatory approval and clinical guidance.

Researchers are also exploring:

• combination hormonal therapies
• longer-acting formulations
• treatments targeting metabolic health more broadly
• personalised approaches based on individual biology and treatment response

Some emerging therapies in international trials are reporting levels of average weight loss approaching those historically associated with bariatric surgery, although long-term safety and effectiveness data are still evolving.

As treatment options expand, ongoing medical oversight and evidence-based prescribing will remain important parts of safe and effective care.

Before starting medical weight loss treatment, patients may wish to ask:

• What type of follow-up care will I receive?
• What side effects should I watch for?
• How long might treatment continue?
• What happens if treatment stops working?
• Can I use my own pharmacy?
• Are pathology tests or referrals needed?
• What lifestyle changes may support treatment outcomes?
• How will progress be monitored over time?

These discussions can help patients better understand the risks, benefits, costs, and expectations associated with treatment.

• Healthdirect Australia
• Better Health Channel
• RACGP Clinical Guidelines
• Therapeutic Goods Administration
• Australian Institute of Health and Welfare

Understand the differences between subscription-style programs and doctor-led medical care.

Compare online weight loss services in Australia

Learn how prescription weight loss injections work, including risks, side effects, and suitability considerations.

Read the GP guide to weight loss injections

Explore the role emotional health and behavioural patterns can play in long-term weight management.

Read about emotional eating and weight management

If you would like personalised medical advice about weight management, Doctors for Weight Loss offers secure telehealth consultations with AHPRA-registered Australian doctors.

Patients can discuss evidence-based treatment options, ongoing monitoring, referrals, and health factors affecting weight management.

Book initial consultation

Last updated: May 2026

This article is general information only and is not a substitute for medical advice. Treatment suitability should always be assessed by a qualified healthcare professional.

• Australian Institute of Health and Welfare. Overweight and obesity
• Healthdirect Australia. Obesity
• Better Health Channel. Obesity
• RACGP. Clinical resources and clinical guidelines
• Therapeutic Goods Administration. Prescription medicines
• Therapeutic Goods Administration. Medicines containing GLP-1 and dual GIP/GLP-1 receptor agonists
• Therapeutic Goods Administration. Manufacturing, supplying and advertising compounded medicines lawfully
• Therapeutic Goods Administration. Counterfeit weight loss products claiming to contain GLP-1
• Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity
• Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes